Roland Meier

Roland Meier

Auto-generated profile, based on publicly available information

Roland Meier

Lawrence Berkeley National Lab, 1 Cyclotron Rd., MS-977-225A, University of California, Berkeley, CA 94720, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2008 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
RMRoland Meier
Roland Meier
MFMarjorie Flahaut
Marjorie Flahaut
KBKatia Balmas Bourloud
Katia Balmas Bourloud
KNKatya Nardou
Katya Nardou
NGNicole Gross
Nicole Gross
Background: Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour agent inhibiting cell proliferation and survival in tumour cells with very low toxicity toward normal cells. Neuroblastoma (NB) is the second most common solid tumour in children still associated with poor outcome in higher stages and, thus NB strongly requires novel treatment modalities. Results: We show here that the HDACi Sodium Butyrate (NaB), suberoylanilide hydroxamic acid (SAHA) and Trichostatin A (TSA) strongly reduce NB cells viability. The anti-tumour activity of these HDACi involved the induction of cell cycle arrest in the G2/M phase, followed by the activation of the intrinsic apoptotic pathway, via the activation of the caspases cascade. Moreover, HDACi mediated the activation of the pro-apoptotic proteins Bid and BimEL and the inactivation of the anti-apoptotic proteins XIAP, Bcl-xL, RIP and survivin, that further enhanced the apoptotic signal. Interestingly, the activity of these apoptosis regulators was modulated by several different mechanisms, either by caspases dependent proteolytic cleavage or by degradation via the proteasome pathway. In addition, HDACi strongly impaired the hypoxia-induced secretion of VEGF by NB cells. Conclusion: HDACi are therefore interesting new anti-tumour agents for targeting highly malignant tumours such as NB, as these agents display a strong toxicity toward aggressive NB cells and they may possibly reduce angiogenesis by decreasing VEGF production by NB cells.

30 March 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GRGilda Raguénez
Gilda Raguénez
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
RMRoland Meier
Roland Meier
CDCaroline Duros
Caroline Duros
JBJean Bénard
Jean Bénard
NGNicole Gross
Nicole Gross
Resistance of high-risk metastatic neuroblastoma (HR-NB) to high dose chemotherapy (HD-CT) raises a major therapeutic challenge in pediatric oncology. Patients are treated by maintenance CT. For some patients, an adjuvant retinoid therapy is proposed, such as the synthetic retinoid fenretinide (4-HPR), an apoptotic inducer. Recent studies demonstrated that NB metastasis process is enhanced by the loss of caspase-8 involved in the Integrin-Mediated Death (IMD) process. As the role of caspase-8 appears to be critical in preventing metastasis, we aimed at studying the effect of 4-HPR on caspase-8 expression in metastatic neuroblasts.

30 April 2009 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
RMRoland Meier
Roland Meier
NGNicole Gross
Nicole Gross